Cantor started coverage of Okta (OKTA) with an Overweight rating, noting that the company is navigating growth challenges ...

In a report released on April 7, Brett Knoblauch from Cantor Fitzgerald maintained a Buy rating on Galaxy Digital Holdings (BRPHF – Research ...

Cantor Fitzgerald views Bob Duggan’s, Summit Therapeutics (SMMT) co-CEO and Chairman, stock option exercise “quite unusual” and “quite bullish” ...

CEO, US Commerce Secretary Howard Lutnick, prevailed in court Thursday against a challenge to the restructuring of BGC ...

Cantor Fitzgerald doubled down on its bearish stance toward stocks on Monday, reaffirming its negative outlook with the statement, “we continue to be bearish on equities.” ...

On Monday, Rivian Automotive Inc (NASDAQ:RIVN), currently valued at approximately $12.7 billion, maintained its Neutral stock rating, as confirmed by analysts at Cantor Fitzgerald. The electric ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Equities research analysts at Cantor Fitzgerald began coverage on shares of Okta (NASDAQ:OKTA – Get Free Report) in a report ...

Cantor Fitzgerald analyst B. Knoblauch now expects that the company will post earnings per share of ($1.06) for the year, down from […] Skip to main content Analyst Ratings ...